These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7768776)

  • 41. [Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections].
    Kobayashi I; Matsuzaki K; Omika K; Hasegawa M; Sato Y
    Jpn J Antibiot; 2007 Apr; 60(2):98-106. PubMed ID: 17612257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.
    Thomson KS; Chartrand SA; Sanders CC; Block SL
    Antimicrob Agents Chemother; 1997 Feb; 41(2):478-80. PubMed ID: 9021213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro susceptibility of six fluoroquinolones against invasive Streptococcus pneumoniae isolated from 1996 to 2001 in Taiwan.
    Chen JY; Fung CP; Wang CC; Chu ML; Siu LK
    Microb Drug Resist; 2003; 9(2):211-7. PubMed ID: 12820807
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activity of telithromycin against 26 quinolone-resistant pneumococci with known quinolone-resistance mechanisms.
    Nagai K; Hoellman D; Davies T; Jacobs M; Appelbaum P
    Clin Microbiol Infect; 2001 Dec; 7(12):703-5. PubMed ID: 11843916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
    Onodera Y; Uchida Y; Tanaka M; Sato K
    J Antimicrob Chemother; 1999 Oct; 44(4):533-6. PubMed ID: 10588315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.
    Esposito S; Noviello S; Ianniello F
    Chemotherapy; 2001; 47(2):90-6. PubMed ID: 11173809
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antipneumococcal activity of grepafloxacin compared to that of other agents by time-kill methodology.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 May; 42(5):1263-5. PubMed ID: 9593163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro susceptibility of anaerobes to quinolones in the United States.
    Hecht DW; Wexler HM
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae.
    Tomizawa H; Tateda K; Miyazaki S; Yamaguchi K
    J Antimicrob Chemother; 1998 Jan; 41(1):103-6. PubMed ID: 9511043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
    Esposito S; Noviello S; Ianniello F
    J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activities of antimicrobial agents against intracellular pneumococci.
    Mandell GL; Coleman EJ
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2561-3. PubMed ID: 10952618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
    Oh JI; Paek KS; Ahn MJ; Kim MY; Hong CY; Kim IC; Kwak JH
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1564-8. PubMed ID: 8726042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
    Yamaguchi K; Miyazaki S; Kashitani F; Iwata M; Kanda M; Tsujio Y; Okada J; Tazawa Y; Watanabe N; Uehara N; Igari J; Oguri T; Kaimori M; Kawamura C; Iinuma Y; Nisawataira T; Tashiro H; Ueno K; Ishigo S; Yasujima M; Kawahara S; Itoh C; Yoshida T; Yamanaka K; Toyoshima S; Katoh J; Kudoh M; Matsushima T; Niki Y; Miyashita N; Funato T; Kaku M; Sato N; Saito Y; Ishii K; Kuwabara M; Hongo T; Negayama K; Kamihira S; Miyazaki Y; Takii M; Ishii M; Nakagawa K; Ono J; Takada T; Murakami N; Taira M; Tamaki I; Matsudou Y; Nakasone I
    Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic activity of trovafloxacin and ceftriaxone or vancomycin against Streptococcus pneumoniae with various penicillin susceptibilities.
    Nicolau DP; Tessier PR; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1998 Apr; 42(4):991-2. PubMed ID: 9559832
    [No Abstract]   [Full Text] [Related]  

  • 56. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.
    Goldsmith CE; Moore JE; Murphy PG; Ambler JE
    J Antimicrob Chemother; 1998 Mar; 41(3):420-1. PubMed ID: 9578174
    [No Abstract]   [Full Text] [Related]  

  • 57. In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.
    Yagupsky P; Katz O; Peled N; Dagan R
    Chemotherapy; 2001; 47(5):354-8. PubMed ID: 11561138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
    Klugman KP; Capper T
    J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
    Weiss K; Laverdiere M; Restieri C
    J Antimicrob Chemother; 1998 Oct; 42(4):523-5. PubMed ID: 9818753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.